Phase 1b dose escalation study of BI 836858 and azacitidine in previously untreated AML: Results from Beat AML S2 Meeting Abstract
| Authors: | Blum, W.; Ruppert, A. S.; Mims, A. S.; Stein, E. M.; Duong, V. H.; Odenike, O.; Patel, P. A.; Kovacsovics, T.; Heerema, N. A.; Vergilio, J. A.; Rosenberg, L.; Marcus, S.; Stefanos, M.; Weiner, H.; Brandt, J.; Shoben, A.; Druker, B. J.; Burd, A.; Levine, R. L.; Byrd, J. C.; Borate, U. |
| Abstract Title: | Phase 1b dose escalation study of BI 836858 and azacitidine in previously untreated AML: Results from Beat AML S2 |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454842803089 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-116199 |
| Notes: | Meeting Abstract: 4053 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work